EP3618819A4 - Gezielte arzneimittelrettung mit neuartigen zusammensetzungen, kombinationen und verfahren dafür - Google Patents

Gezielte arzneimittelrettung mit neuartigen zusammensetzungen, kombinationen und verfahren dafür Download PDF

Info

Publication number
EP3618819A4
EP3618819A4 EP18794381.6A EP18794381A EP3618819A4 EP 3618819 A4 EP3618819 A4 EP 3618819A4 EP 18794381 A EP18794381 A EP 18794381A EP 3618819 A4 EP3618819 A4 EP 3618819A4
Authority
EP
European Patent Office
Prior art keywords
combinations
methods
novel compositions
targeted drug
drug rescue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18794381.6A
Other languages
English (en)
French (fr)
Other versions
EP3618819A1 (de
Inventor
Sreenivasarao Vepachedu
Hans J. MOEBIUS
Anton Bespalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exciva GmbH
Original Assignee
Exciva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by Exciva GmbH filed Critical Exciva GmbH
Publication of EP3618819A1 publication Critical patent/EP3618819A1/de
Publication of EP3618819A4 publication Critical patent/EP3618819A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
EP18794381.6A 2017-05-04 2018-05-03 Gezielte arzneimittelrettung mit neuartigen zusammensetzungen, kombinationen und verfahren dafür Pending EP3618819A4 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (2)

Publication Number Publication Date
EP3618819A1 EP3618819A1 (de) 2020-03-11
EP3618819A4 true EP3618819A4 (de) 2021-01-20

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18794381.6A Pending EP3618819A4 (de) 2017-05-04 2018-05-03 Gezielte arzneimittelrettung mit neuartigen zusammensetzungen, kombinationen und verfahren dafür

Country Status (13)

Country Link
EP (1) EP3618819A4 (de)
JP (2) JP2020518617A (de)
KR (2) KR102444803B1 (de)
CN (1) CN110831584B (de)
AU (2) AU2018261654A1 (de)
BR (1) BR112019022902A2 (de)
CA (2) CA3062452C (de)
IL (1) IL270326B2 (de)
MA (1) MA49464A (de)
RU (1) RU2760558C9 (de)
TW (1) TWI787260B (de)
WO (1) WO2018204713A1 (de)
ZA (1) ZA201908006B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202102219A (zh) * 2019-03-18 2021-01-16 美商艾賓爾製藥公司 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
CA2903757A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
JP2016516202A (ja) * 2013-03-15 2016-06-02 キネメッド， インコーポレイテッド バイオマーカー
CA3034895A1 (en) * 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschrankt) Compositions and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296 *
MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024 *
SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141 *

Also Published As

Publication number Publication date
TWI787260B (zh) 2022-12-21
RU2760558C9 (ru) 2022-02-22
CN110831584A (zh) 2020-02-21
CN110831584B (zh) 2023-03-10
BR112019022902A2 (pt) 2020-05-19
AU2021215274B2 (en) 2022-11-03
WO2018204713A1 (en) 2018-11-08
RU2760558C2 (ru) 2021-11-29
EP3618819A1 (de) 2020-03-11
CA3062452C (en) 2023-10-24
MA49464A (fr) 2020-04-29
RU2019137004A3 (de) 2021-06-04
ZA201908006B (en) 2021-04-28
AU2018261654A1 (en) 2019-11-14
JP2023143940A (ja) 2023-10-06
KR102444803B1 (ko) 2022-09-19
KR20210130827A (ko) 2021-11-01
IL270326B (en) 2022-10-01
IL270326B2 (en) 2023-02-01
TW201842902A (zh) 2018-12-16
JP2020518617A (ja) 2020-06-25
IL270326A (de) 2018-05-03
KR20200062078A (ko) 2020-06-03
CA3138116A1 (en) 2018-11-08
RU2019137004A (ru) 2021-06-04
AU2021215274A1 (en) 2021-09-02
CA3062452A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
EP3463386A4 (de) Oligonukleotide, zusammensetzungen und verfahren dafür
EP3665156A4 (de) Verbindungen, zusammensetzungen und verfahren
EP3313404A4 (de) Therapeutische zusammensetzungen, kombinationen und verfahren zur verwendung
EP3485068A4 (de) Elektrochemische verfahren, vorrichtungen und zusammensetzungen
EP3315608A4 (de) Sirna, pharmazeutische zusammensetzung und konjugat mit sirna und verwendungen davon
EP3676297A4 (de) Verbindungen, zusammensetzungen und verfahren
EP3297637A4 (de) Benzol-1,3,5-tricarboxamidderivate und verwendungen davon
EP3161124A4 (de) Endophyten, entsprechende zusammensetzungen und verfahren zur verwendung davon
EP3313530A4 (de) 4,6-pyrimidinylenderivate und verwendung davon
EP3491026A4 (de) Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
EP3100731A4 (de) Ligandzytotoxizitätswirkstoffkonjugat, herstellungsverfahren dafür und verwendungen davon
EP3137168A4 (de) Substituierte 4-phenylpiperidine, deren herstellung und verwendung
EP3131131A4 (de) Lichtemissionselement und darin verwendete zusammensetzung
EP3159344A4 (de) Amino-pyranoid-ringderivat und zusammensetzung und verwendung davon
EP3723763A4 (de) Anti-cd22-antikörper-maytansin-konjugate, kombinationen und verfahren zur verwendung davon
EP3381925A4 (de) Deuteriummodifizierte brigatinibderivate, pharmazeutische zusammensetzungen damit und verwendung davon
EP3395366A4 (de) Wirkstoffdesignverfahren, erhaltener wirkstoff und anwendung davon
EP3162835A4 (de) Monomerzusammensetzung und härtbare zusammensetzung damit
EP3359676A4 (de) Transposonsystem, kit damit und verwendungen davon
EP3699179A4 (de) Pyrazolhaltiges tricyclisches derivat, herstellungsverfahren dafür und verwendung davon
EP3449924A4 (de) Zusammensetzung, aktives zentrum von crocinen und verwendungen davon
EP3239183A4 (de) Modifiziertes konjugiertes dienpolymer und polymerzusammensetzung mit diesem polymer
ZA201908006B (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3554504A4 (de) Substituierte pyrazolpyrimidine, varianten davon und verwendungen davon
EP3386988A4 (de) Neuartige dihydropyranylpyrimidinonderivate und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20191203

Extension state: TN

Effective date: 20191203

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015233

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031135000

Ipc: A61K0031138000

A4 Supplementary search report drawn up and despatched

Effective date: 20201217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/225 20060101ALI20201211BHEP

Ipc: A61K 47/60 20170101ALI20201211BHEP

Ipc: A61K 9/20 20060101ALI20201211BHEP

Ipc: A61K 47/36 20060101ALI20201211BHEP

Ipc: A61K 31/485 20060101ALI20201211BHEP

Ipc: A61K 31/195 20060101ALI20201211BHEP

Ipc: A61K 45/06 20060101ALI20201211BHEP

Ipc: A61K 31/13 20060101ALI20201211BHEP

Ipc: A61K 31/138 20060101AFI20201211BHEP

Ipc: A61P 25/00 20060101ALI20201211BHEP

Ipc: A61K 31/439 20060101ALI20201211BHEP

Ipc: A61P 9/00 20060101ALI20201211BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231123